Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07391605 · ClinicalTrials.gov registry record · Phase 2
Descartes-08 in Autoantibody Myositis
A Phase 2 study, sponsored by Cartesian Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07391605 is a Phase 2 study that is actively recruiting participants, run by Cartesian Therapeutics. The registered enrollment target is 60 participants.
The verdict
NCT07391605, a Phase 2 study, is actively recruiting participants, sponsored by Cartesian Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).
Interventions
- OTHER Placebo
- DRUG Descartes-08
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04-28 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07391605
The ClinicalTrials.gov registry entry for NCT07391605 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cartesian Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07391605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07391605 about?
NCT07391605 is a clinical study titled "Descartes-08 in Autoantibody Myositis". This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisyn...
What is the current status of trial NCT07391605?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-04-28. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07391605?
The interventions under investigation include: Placebo (OTHER), Descartes-08 (DRUG).
Who is sponsoring clinical trial NCT07391605?
This trial is sponsored by Cartesian Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.